LLY

733.87

+2.71%↑

JNJ

149.53

+2.14%↑

UNH

273.23

-11.3%↓

ABBV

181.65

+2.56%↑

NVO

66.05

+2.69%↑

LLY

733.87

+2.71%↑

JNJ

149.53

+2.14%↑

UNH

273.23

-11.3%↓

ABBV

181.65

+2.56%↑

NVO

66.05

+2.69%↑

LLY

733.87

+2.71%↑

JNJ

149.53

+2.14%↑

UNH

273.23

-11.3%↓

ABBV

181.65

+2.56%↑

NVO

66.05

+2.69%↑

LLY

733.87

+2.71%↑

JNJ

149.53

+2.14%↑

UNH

273.23

-11.3%↓

ABBV

181.65

+2.56%↑

NVO

66.05

+2.69%↑

LLY

733.87

+2.71%↑

JNJ

149.53

+2.14%↑

UNH

273.23

-11.3%↓

ABBV

181.65

+2.56%↑

NVO

66.05

+2.69%↑

Search

Microbot Medical Inc

Gesloten

2.62 6.94

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

2.43

Max

2.64

Belangrijke statistieken

By Trading Economics

Inkomsten

-177K

-3.4M

EPS

-0.2

Werknemers

20

EBITDA

-127K

-3.4M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+265.85% upside

Dividenden

By Dow Jones

Volgende Winsten

20 mei 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

37M

93M

Vorige openingsprijs

-4.32

Vorige sluitingsprijs

2.62

Technische score

By Trading Central

Vertrouwen

Neutral Evidence

Microbot Medical Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

15 mei 2025, 22:52 UTC

Winsten
Belangrijke Marktbewegers

Virgin Galactic Shares Rise on Commercial Spaceflight Plans, Narrower 1Q Loss

15 mei 2025, 20:37 UTC

Top Nieuws
Winsten

Applied Materials Logs Higher 2Q Profit, Revenue as Customer Demand Remains Unchanged

16 mei 2025, 00:00 UTC

Marktinformatie

Xero Bull Stays Positive on Cost Outlook -- Market Talk

15 mei 2025, 23:47 UTC

Marktinformatie

Gold Consolidates; Likely Supported by Signs of Disinflation -- Market Talk

15 mei 2025, 23:38 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

15 mei 2025, 23:38 UTC

Marktinformatie

Nikkei May Edge Higher, Tracking Gains Across Most U.S. Equity Markets -- Market Talk

15 mei 2025, 23:14 UTC

Top Nieuws

Walmart Becomes Biggest Retailer Yet to Pass Through Tariff Price Increases -- 4th Update

15 mei 2025, 22:46 UTC

Top Nieuws
Acquisities, Fusies, Overnames

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

15 mei 2025, 22:46 UTC

Acquisities, Fusies, Overnames

Bayer Working With Restructuring Advisers Latham, AlixPartners to Explore Options for Monsanto -- WSJ

15 mei 2025, 22:46 UTC

Acquisities, Fusies, Overnames

Bayer Exec Says Company Committed to Resolving Roundup Lawsuits in 18 Months -- WSJ

15 mei 2025, 22:46 UTC

Acquisities, Fusies, Overnames

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

15 mei 2025, 21:58 UTC

Winsten

Applied Materials Earnings Beat Expectations. Why the Stock Is Down. -- Barrons.com

15 mei 2025, 21:24 UTC

Winsten

Cava's Earnings Beat Expectations. Growth Was Strong Despite Tariff Fears. -- Barrons.com

15 mei 2025, 20:56 UTC

Marktinformatie

U.S. Spending Downturn Could Lie Ahead -- Market Talk

15 mei 2025, 20:54 UTC

Marktinformatie
Winsten

Applied Materials CFO Says Demand Stable Despite Tariffs, Macro -- Market Talk

15 mei 2025, 20:54 UTC

Winsten

Applied Materials Investing to Support Semiconductor Market of More Than $1T by End of Decade, Financial Chief Says

15 mei 2025, 20:51 UTC

Winsten

Applied Materials Financial Chief: Long-Term Secular Growth Drivers Remain Intact

15 mei 2025, 20:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

15 mei 2025, 20:50 UTC

Acquisities, Fusies, Overnames

Berkshire Sells Financial Stocks, Doubles Constellation Stake, Holds Steady on Apple -- WSJ

15 mei 2025, 20:50 UTC

Winsten

Applied Materials' Customer Investments Continue at Expected Rate and Pace, Financial Chief Says

15 mei 2025, 20:47 UTC

Winsten

Applied Materials Not Currently Seeing Large Changes in Customer Demand, CEO Says

15 mei 2025, 20:47 UTC

Winsten

Applied Materials Sees Revenue From Advanced DRAM Customers to Grow 40% in FY25, CEO Says

15 mei 2025, 20:47 UTC

Winsten

Applied Materials Grew Faster Than Peers in Markets Outside China in 2Q, CEO Says

15 mei 2025, 20:47 UTC

Winsten

Applied Materials Underperformed Market in China in 2Q Due to Restrictions on U.S. Companies, CEO Says

15 mei 2025, 20:37 UTC

Winsten

SOS Ltd: Growth Was Fueled by Robust Domestic Demand and Expansion of Pdt Portfolio to Include Rubber and Coal >SOS

15 mei 2025, 20:37 UTC

Winsten

SOS Ltd: Cryptocurrency Mining Rev Declined to $9.3M From $18.9M in FY23, Dip Was Attributed to the Temporary Shutdown of Texas Mining Facility for Upgrades During 1H 2024 >SOS

15 mei 2025, 20:37 UTC

Winsten

SOS Ltd: FY24 Significant Yr-over-Yr Increase in Commodity Trading Rev, Which Soared to $214.3M FY24, 92.6% of Total Rev Up From 74.0% in FY23 >SOS

15 mei 2025, 20:37 UTC

Winsten

SOS Ltd: Cryptocurrency Mining Rev Halves as SOS Focuses on Facility Upgrades and Commodity Expansion >SOS

15 mei 2025, 20:26 UTC

Top Nieuws

Trump Presses Apple to Bring iPhone Manufacturing to America. Wall Street Shrugs. -- WSJ

15 mei 2025, 20:25 UTC

Winsten

Deere Stock Jumps on Guidance Cut. Here's Why. -- Barrons.com

Peer Vergelijking

Prijswijziging

Microbot Medical Inc Prognose

Koersdoel

By TipRanks

265.85% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 9 USD  265.85%

Hoogste 9 USD

Laagste 9 USD

Gebaseerd op 1 Wall Street-analisten die 12-maands prijsdoelen bieden voor Microbot Medical Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

1 ratings

1

Buy

0

Hold

0

Sell

Technische score

By Trading Central

2.52 / 2.57Steun & Weerstand

Korte Termijn

Neutral Evidence

Gemiddeld Termijn

Very Strong Bullish Evidence

Lange Termijn

Weak Bullish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Microbot Medical Inc

Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development; and Phase 2 collaboration agreement with Corewell Health for the development of LIBERTY endovascular robotic system. Microbot Medical Inc. was founded in 2010 and is based in Braintree, Massachusetts.